Wegovy & Ozempic: Weight Loss Drugs Linked to Higher Risk of Sudden Vision Loss

Patients taking Wegovy for weight loss may face a significantly elevated risk of sudden sight loss compared to those using Ozempic for diabetes management, according to a new large-scale study published in the British Journal of Ophthalmology. The research indicates Wegovy users experienced a nearly fivefold increase in cases of non-arteritic anterior ischemic optic neuropathy (Naion), often referred to as an “eye stroke,” compared to Ozempic users. This finding adds to a growing body of scrutiny surrounding the safety profile of GLP-1 receptor agonist medications, a class of drugs that includes both Wegovy and Ozempic, as well as others like Rybelsus and Mounjaro.

Understanding Non-Arteritic Anterior Ischemic Optic Neuropathy (Naion)

Naion occurs when blood flow to the optic nerve is disrupted, leading to sudden, often permanent, vision loss. The Imperial NHS leaflet describes it as a condition affecting around one in 10,000 people taking semaglutide, though the study suggests a potential link to dosage. While relatively rare, the potential for vision loss understandably raises concerns for patients and prescribers alike.

Study Details and Findings

The study, led by researchers at the University of Toronto, analyzed reports of adverse events submitted to the US Food and Drug Administration (FDA) between December 2017 and December 2024. Researchers compared Naion reports associated with different dosages and formulations of semaglutide: up to 2mg of weekly injectable Ozempic (for type 2 diabetes), up to 2.4mg of weekly injectable Wegovy (for obesity), and a daily Rybelsus tablet (similarly for type 2 diabetes). They also examined reports related to tirzepatide (Mounjaro).

The analysis revealed that Wegovy demonstrated the strongest association with sudden vision loss. Notably, the study found no increased risk associated with Rybelsus tablets or tirzepatide. This difference is potentially linked to the higher doses used in Wegovy and the faster-acting nature of injections, as opposed to the slower absorption of the Rybelsus tablet.

Regulatory Scrutiny and Safety Updates

The findings have prompted increased attention from regulatory bodies. In February 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety update warning about the risk of Naion associated with semaglutide. This followed similar warnings from the European Medicines Agency (EMA). Dr. Alison Cave, the MHRA chief safety officer, emphasized that while the risk remains extremely low, both patients and prescribers should be aware of the potential symptoms.

What the Findings Do – and Don’t – Tell Us

It’s crucial to understand the limitations of this study. As consultant ophthalmologist Samantha Mann of the Royal College of Ophthalmologists points out, the research relies on reported side effects, which cannot definitively prove a causal relationship. The study demonstrates an association, but doesn’t establish that semaglutide *causes* Naion. It’s possible that other factors contribute to the increased risk observed in Wegovy users. The study’s findings may not fully reflect the true incidence of Naion, as not all cases may be reported.

The study also highlights a potential “dose-dependent safety concern,” suggesting that higher doses of semaglutide, like those used in Wegovy, may carry a greater risk. Dr. Edward Margolin, from the University of Toronto’s department of ophthalmology, suggests that faster or more aggressive weight loss could also increase the risk of Naion. This observation underscores the importance of individualized treatment plans and careful monitoring of patients on these medications.

GLP-1 Agonists: A Broader Context

GLP-1 receptor agonists like semaglutide and tirzepatide have gained widespread popularity for their effectiveness in managing type 2 diabetes and promoting weight loss. These medications work by reducing blood sugar levels, slowing digestion, and suppressing appetite. Recent research has even linked them to reduced risks of heart attack and fewer drug overdoses. However, as with any medication, potential side effects must be carefully considered.

Novo Nordisk’s Response

Novo Nordisk, the manufacturer of Wegovy, Ozempic, and Rybelsus, has acknowledged the findings and stated that patient safety is their top priority. A spokesperson for the company emphasized their close collaboration with regulatory authorities to continuously monitor the safety profile of their products. Novo Nordisk has updated the patient leaflets for Wegovy, Ozempic, and Rybelsus to include information about Naion, but maintains that the available evidence does not establish a causal link between semaglutide and the condition, and that the benefit-risk profile remains favorable.

What to Discuss with Your Clinician

If you are currently taking Wegovy, Ozempic, Rybelsus, or Mounjaro, it’s important to discuss these findings with your healthcare provider. Do not stop or adjust your medication without professional guidance. Be sure to report any sudden changes in vision to your doctor immediately. Understanding the potential risks and benefits of these medications is crucial for making informed decisions about your health.

Ongoing surveillance and further research are essential to better understand the potential link between GLP-1 agonists and Naion. Regulatory agencies will continue to monitor adverse event reports and update guidance as new information becomes available. Patients and healthcare providers should remain vigilant and prioritize open communication to ensure the safest possible use of these medications.